^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA anti-MLH-1 (M1) Mouse Monoclonal Primary Antibody

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    Details
    Evidence

    News

    2ms
    Clinicopathologic Characterization of Claudin 18.2 Expression in Surgically-Resected Gastric and Esophageal Adenocarcinomas (USCAP 2024)
    CLDN18.2+ expression is associated with early stage GACs, but with metastatic disease in E/GEJACs. CLDN18.2+ expression is not affected by preoperative treatment or HER2 status. These findings expand our recognition of subsets of patients who may benefit from targeted CLDN18.2 therapy.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    HER-2 positive • HER-2 negative • HER-2 expression • CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody • VENTANA anti-MLH-1 (M1) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody • VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody
    1year
    Expression of Programmed Cell-Death Ligand 1 (PD-L1) and Analysis of Microsatellite Instability/ DNA Mismatch Repair (MSI/MMR) Status in Penile Squamous Cell Carcinoma (PC) (USCAP 2023)
    The expression of PD-L1 was associated with high grade tumour, lymph nodal metastasis, LVI and nodal stage, hence propends for creating targeted therapy with ICI. dMMR, however was noted only in 2% of cases which showed high PDL1 expression.
    Microsatellite instability • PD(L)-1 Biomarker • IO biomarker • Mismatch repair
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PMS2 (PMS1 protein homolog 2)
    |
    PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay • VENTANA anti-MLH-1 (M1) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody • VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody
    over1year
    Expression of Programmed Cell-Death Ligand 1 (PD-L1) and Analysis of Microsatellite Instability/ DNA Mismatch Repair (MSI/MMR) Status in Penile Squamous Cell Carcinoma (PC) (USCAP 2023)
    The expression of PD-L1 was associated with high grade tumour, lymph nodal metastasis, LVI and nodal stage, hence propends for creating targeted therapy with ICI. dMMR, however was noted only in 2% of cases which showed high PDL1 expression.
    Microsatellite instability • PD(L)-1 Biomarker • IO biomarker • Mismatch repair
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PMS2 (PMS1 protein homolog 2)
    |
    PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay • VENTANA anti-MLH-1 (M1) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody • VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody • VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody